Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Driehaus Mutual

Driehaus Small Cap Growth Fund Investor Share Class (DVSMX)

Ticker DVSMX · · Holdings as of Jun 30, 2026

Expense ratio
0.93%$93/yr per $10k
5-yr return
+7.1%annualized
1-yr return
+16.7%as of Dec 2025
Net assets
$1.6Ball share classes
Holdings
122

Bottom line

Is DVSMX a good fund? The bottom line

DVSMX is the Investor Share Class share class of Driehaus Small Cap Growth Fund, a managed small-cap mutual fund from Driehaus Mutual.

Annual fees run 0.93% — about $93 a year on every $10,000 invested, cheaper than 58% of small-cap funds we track.

It returned +16.7% over one year, +7.1% a year over five years, +17.1% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.6 billion in net assets and 122 holdings, its largest position is Northern Institutional Funds (2.7%) and the top 10 make up 18.9% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • High turnover (152% a year) can mean more taxable distributions

Updated Nov 19, 2026

What DVSMX invests in

Driehaus Small Cap Growth Fund seeks to maximize capital appreciation.

The Fund uses a growth style of investment in equity securities, including common stocks and other equity securities of issuers. Under normal market conditions, the Fund invests at least 80% of its net assets (plus the amount of borrowings for investment purposes) in the equity securities of U.S. small-capitalization (small-cap) companies. For purposes of the Fund, the investment adviser considers a company to be a small cap company if it is within the same market capitalization range at the time of investment as those included in the Russell 2000 Growth Index. For the avoidance of doubt, while the reference index is float-adjusted, meaning it excludes closely held and other shares unavailable to investors, the investment adviser does not consider a float-adjustment when determining the market capitalization of a company. As of March 31, 2026, approximately 86% of the Russell 2000…

From the fund's prospectus (filed Apr 29, 2026).

DVSMX performance

Fund calendar-year total returns, 2016–2025 2016: +10.7%; 2017: +30.7%; 2018: +3.3%; 2019: +40.3%; 2020: +63.8%; 2021: +21.1%; 2022: −34.1%; 2023: +18.9%; 2024: +27.4%; 2025: +16.7% +11% 2016 +31% 2017 +3% 2018 +40% 2019 +64% 2020 +21% 2021 −34% 2022 +19% 2023 +27% 2024 +17% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
DVSMX+16.7%+7.1%+17.1%
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full DVSMX performance history →

What DVSMX costs

On a $10,000 investment, DVSMX's 0.93% expense ratio costs about $93 a year. The prospectus estimates $1,143 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full DVSMX fee table →

DVSMX top 10 holdings

#Holding% of fund
1Northern Institutional Funds2.71%
2Vicor Corp VICR2.03%
3Guardant Health Inc GH1.99%
4Silicon Motion Technology Corp SIMO1.98%
5Apogee Therapeutics Inc APGE1.81%
6Praxis Precision Medicines Inc PRAX1.75%
7Definium Therapeutics Inc DFTX1.74%
8Planet Labs Pbc PL1.73%
9Spyre Therapeutics Inc SYRE1.70%
10Curtiss-wright Corp CW1.49%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 18.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to DVSMX

More funds like DVSMX →

DVSMX FAQ

What is the expense ratio of DVSMX?
DVSMX's expense ratio is 0.93%, which works out to about $93 a year for every $10,000 invested. The prospectus estimates total costs of $1,143 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is DVSMX a good investment?
It depends on your goals, but the data points to: no front-end sales load; high turnover (152% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does DVSMX hold?
DVSMX's largest holdings are Northern Institutional Funds (2.7%), Vicor Corp (2.0%), Guardant Health Inc (2.0%), Silicon Motion Technology Corp (2.0%), Apogee Therapeutics Inc (1.8%). It holds 122 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is DVSMX's 5-year return?
DVSMX returned +7.1% a year over the five years ending Dec 31, 2025, and +17.1% a year over ten years. Past performance does not guarantee future results.
Does DVSMX have a sales load?
No. DVSMX has no front-end sales charge.
Who manages DVSMX?
DVSMX is offered by Driehaus Mutual through Driehaus Mutual Funds.